In this prospective, open-label, non-controlled, clinical trial, researchers analyzed 49 candidates to estimate the 4-year consequences of aflibercept in treatment-resistant neovascular age-related macular degeneration (nAMD). They calculated best-corrected visual acuity (BCVA), central retinal thickness (CRT), pigment epithelial detachment (PED) height and geographic atrophy (GA) surface area. They observed a reduction in CRT from baseline, 170.3 ± 143.3 μm with the absence of macular fluid in 56% of eyes at the end of 48 months. A decline in PED by a mean 77.5 ± 20.0 μm whereas an incline in geographic atrophy by a mean of 4.1 ± 3.4 mm2 was noted over the 48 months. They concluded aflibercept, efficient alternative therapy as good anatomical and stable functional responses were achieved.
Read the full article on Acta Ophthalmologica